However, CD8+ T cells outnumbered Tregs in the tumor of PD1-IL2v-treated mice, as shown in the above-mentioned studies using pancreatic cancer and lymphoma models [7–10]; the resulting anti-cancer effect was evidenced by the prolonged survival and/or reduced tumor burden of mice. This evidence concerns the gene CD8A and neoplasm.